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Abstract Causative genetic variants have to date been
identiﬁed for only a small proportion of familial colorectal
cancer (CRC). While conditions such as Familial Ade-
nomatous Polyposis and Lynch syndrome have well
deﬁned genetic causes, the search for variants underlying
the remainder of familial CRC is plagued by genetic het-
erogeneity. The recent identiﬁcation of families with a
heritable predisposition to malignancies arising through the
serrated pathway (familial serrated neoplasia or Jass
syndrome) provides an opportunity to study a subset of
familial CRC in which heterogeneity may be greatly
reduced. A genome-wide linkage screen was performed on
a large family displaying a dominantly-inherited predis-
position to serrated neoplasia genotyped using the
Affymetrix GeneChip Human Mapping 10 K SNP Array.
Parametric and nonparametric analyses were performed
and resulting regions of interest, as well as previously
reported CRC susceptibility loci at 3q22, 7q31 and 9q22,
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DOI 10.1007/s10689-010-9408-8were followed up by ﬁnemapping in 10 serrated neoplasia
families. Genome-wide linkage analysis revealed regions
of interest at 2p25.2-p25.1, 2q24.3-q37.1 and 8p21.2-
q12.1. Finemapping linkage and haplotype analyses iden-
tiﬁed 2q32.2-q33.3 as the region most likely to harbour
linkage, with heterogeneity logarithm of the odds (HLOD)
2.09 and nonparametric linkage (NPL) score 2.36
(P = 0.004). Five primary candidate genes (CFLAR,
CASP10, CASP8, FZD7 and BMPR2) were sequenced and
no segregating variants identiﬁed. There was no evidence
of linkage to previously reported loci on chromosomes 3, 7
and 9.
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MMR Mismatch repair
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Introduction
The identiﬁcation of a causative genetic variant in cancer-
prone families such as those with Lynch syndrome is an
important determinant of decreased mortality through more
focussed cancer surveillance [1]. In addition, colorectal
cancers (CRC) arising in Lynch syndrome show molecular
and pathology features, such as immunohistochemical loss
of DNA mismatch repair (MMR) gene expression and
increased tumour inﬁltrating lymphocytes, which allow
them to be distinguished from among unselected series.
However, less than 3% of all CRC is accounted for by this
well-characterised condition, in which the cancers develop
from adenomatous polyps [2, 3].
Several studies examining linkage in non-syndromic
CRC families have reported statistically signiﬁcant asso-
ciations at 3q22 [4–7] and 9q22 [8–11]. A more recent
study found linkage to 7q31 in colorectal neoplasia fami-
lies, and conﬁrmed the region at 3q22 as a susceptibility
locus for CRC [12]. To date no conﬁrmed causative vari-
ants have been identiﬁed from these regions, though the
reported associations remain robust.
The balance of families with CRC predisposition are
likely to show genetic heterogeneity and variable pene-
trance, thereby limiting the power of genome-wide linkage
approaches to deﬁne critical regions in the absence of
stratiﬁcation. The description of families with multiple
cases of neoplasia in which serrated polyps are prominent
has facilitated the exploration of a proportion of the
remaining unexplained familial aggregation. Such families
were initially reported from New Zealand by the late
Professor Jass and colleagues in the mid-nineties [13, 14],
and a further publication demonstrated the familial
involvement of hyperplastic polyposis [15], associated with
LOH at chromosome 1p. Families fulﬁlling the Amsterdam
I criteria with mixed epithelial polyps and variable levels
of microsatellite instability (MSI) in which Lynch syn-
drome could be excluded, and which showed some overlap
with hyperplastic polyposis, were reported in 2005 [16].
Such families are characterised by a mixture of serrated
and adenomatous polyps, and, in contrast to Lynch syn-
drome, somatic BRAF mutation is commonly observed in
CRC. Only a minority of cancers demonstrate MMR deﬁ-
ciency, attributable to methylation of the MLH1 gene
promoter. We refer to this condition of serrated neoplasia
and adenomas clustering in families as Jass syndrome, after
the pathologist who ﬁrst described it [13, 14].
Studies on unselected series of CRCs have shown that
molecular features of the serrated pathway, such as wide-
spread CpG island methylation and somatic BRAF muta-
tion, as well as the presence of serrated lesions with atypical
histology (sessile serrated adenomas), are associated with a
family history of CRC [17–19], lending further support to
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123the idea that the observed familial aggregation of lesions
arising through the serrated pathway is the result of an
inherited predisposition. In addition, the presence of a ses-
sile serrated adenoma is associated with polyp multiplicity
[19, 20], and with conventional adenomas in patients who
do not meet the criteria for hyperplastic polyposis [21]. In
patients with hyperplastic polyposis, polyps with ade-
nomatous elements increase the risk of CRC [22–24], and
are the likely lesions of origin for at least some of the
cancers occurring in this condition [25].
We have investigated genomic regions associated with
Jass syndrome by performing a genome-wide linkage
screen in a single large family, followed by ﬁnemapping in
a further 10 families, and present evidence for linkage to
chromosome 2q32.2-q33.3. Through further ﬁnemapping
analysis, we also provide evidence that previously reported
CRC susceptibility loci at 3q22, 7q31 and 9q22 are unli-
kely to contribute to Jass syndrome.
Materials and methods
Families
The 11 families in this study, ﬁve of which have been
described previously [16], were enrolled from high-risk
genetics clinics in Australia as part of the Colon Cancer
Family Registry, an international collaborative registry for
the study of genetics and epidemiology of colorectal cancer
[26]. All participants gave written informed consent to take
part in research, and the project was performed under
QIMR Human Research Ethics Committee Approval P912
(Genetics of Serrated Neoplasia).
Polyps were reviewed by a specialist gastro-intestinal
pathologist (JRJ). MSI status of tumours was determined
using a panel of 10 microsatellite markers (BAT-25, BAT-
26, BAT-34C4, BAT-40, D5S346, D10S197, D17S250,
D18S55, ACTC and MYCL) and standard techniques [16,
27]. BRAF V600E mutation status of tumours was analysed
as previously described [28]. Lynch syndrome was exclu-
ded in all families as determined by: (1) proﬁcient
expression of the MMR proteins in tumours; (2) absence of
pathogenic mutations or variants of uncertain clinical sig-
niﬁcance in the MMR genes after sequencing of the coding
and splice site regions and MLPA analysis for large dele-
tions or duplications; and (3) methylation analysis of the
MLH1 gene promoter. No mutations were found in any
patients. Three cancers showed loss of MLH1 protein
expression, of which two had sufﬁcient DNA available for
methylation analysis and tested positive for methylation of
the MLH1 promoter in their tumour tissue [29].
Criteria for inclusion of families were: at least 2 indi-
viduals with CRC, with one aged under 60 years; AND at
least 2 individuals with polyps, with one aged under
60 years; AND at least two of the following characteristics
associated with serrated neoplasia:
1. a mixture of hyperplastic and adenomatous polyps;
2. variable levels of MSI in cancers and/or polyps
3. the presence of BRAF V600E somatic mutation in one
or more cancers; and
4. at least one individual with multiple hyperplastic
polyps under age 60.
Characteristics of each family are listed in Table 1.
Genome-wide linkage screen
The 10 K Xba 142 GeneChip Human Mapping Array (Af-
fymetrix Inc., Santa Clara, CA, USA) was used to genotype
seven affected individuals and one unaffected spouse from
Family 1 (Fig. 1), a multi-case CRC family with multiple
young-onset, BRAF-mutated, MSI-variable (MSI-V) CRCs,
and multiple individuals with multiple serrated polyps or
those with atypical histology including sessile serrated
adenomas, serrated adenomas, and mixed polyps [16, 25].
Sample call rates were all greater than 98.5%, with a total of
990 no calls, and 1280 SNPs (1.3%) were uninformative in
the pedigree. Sex was veriﬁed by observing heterozygosity
rates of X-linked markers. PedCheck [30] was used to
detect Mendelian errors, which were manually corrected via
the removal of inconsistent genotypes.
Both parametric and nonparametric (NPL) linkage
analyses were performed using GeneHunter version 2.1
[31] via a stepwise 900 SNP sliding window, implemented
in the Alohomora GUI interface [32]. For parametric
analysis, an autosomal dominant mode of inheritance was
speciﬁed, with 60% penetrance, 10% phenocopy rate and a
disease allele frequency of 0.001. Families segregating
serrated neoplasia show clustering of CRC, including those
with somatic BRAF mutation, and polyps of adenomatous,
serrated and mixed histology. Individuals with CRC and/or
large, multiple or atypical serrated polyps, or any serrated
or adenomatous polyp diagnosed before age 60, were
classed as affected. As the prevalence of adenomas in the
population increases with age [33], a conservative
approach was taken to the classiﬁcation of affected indi-
viduals in the over 60 age group, requiring adenomas to be
5 mm or greater in size, or have villous components, and
excluding individuals with diminutive rectal-only lesions.
Haplotypes were constructed in GeneHunter and viewed
graphically using HaploPainter version 029.5 [34].
Finemapping
Twelve microsatellite markers on chromosome 2p, 22
markers on 2q, 18 markers on chromosome 3, 10 markers
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123on chromosome 7, 12 markers on chromosome 8 and 13
markers on chromosome 9 were typed in the 11 families.
Markers and primer sequences are listed in Supplementary
Table 1. Markers were ampliﬁed using True Allele PCR
Premix (Applied Biosystems, Foster City, CA, USA) or
GoTaq Colorless Master Mix (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. PCR
products were labelled with FAM, HEX or NED ﬂuoro-
phores, either by labelling one primer in each pair or via an
M13 tag and labelled M13 primer, and separated using an
ABI 3100 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). Data were analysed using GeneMarker
version 1.70 or 1.75 (SoftGenetics, PA, USA). Mendelian
error checking was performed using Progeny Lab 6
(Progeny Software, South Bend, IN, USA). Non-Mendelian
error checking and parametric and nonparametric linkage
analyses on full pedigrees were performed using SimWalk
2.91 [35], implemented under the easyLINKAGE Plus
Table 1 Phenotypic characteristics of families
Family Individuals
with CRC
CRC ages Polyp ages
(and numbers)
MSI-V BRAF
CRC
Hyperplastic
and adenomatous
polyps
Individuals with
multiple hyperplastic
polyps under
60 (ages)
Evidence
of linkage
to Region 1
1 3 45, 53, 74 63 (1), 53 (3), 51 (2), 57 (2),
46 (1)
Yes Yes Yes 1 (57) Yes
2a
a 32 5
a,3 1
a, 32 29 (1), 53 (1) No No Yes 0 Yes
2b
a 82 5
a,3 1
a, 54, 72,
53, 65, 63, 52
57 (10), 53 (2), 63 (1) No Yes Yes 1 (57) No
3 4 52, 65, 67, 70 71(1), 66 (1), 65 (7), 55 (11),
60 (2), 49 (1)
No No Yes 1 (55) No
4 4 37, 44, 58, 62 37 (2), 57 (11), 51 (4), 58 (5) No No Yes 3 (51, 57, 58) No
5 4 31, 47, 52, 59 49 (1), 38 (1), 45 (2), 50 (7),
28 (1)
Yes No Yes 1 (50) Yes
6 3 43, 53, 74 53 (6), 43 (4), 52 (4) Yes Yes Yes 2 (52, 53) Yes
7 4 31, 39, 50, 61 49 (2), 31 (2) No No Yes 1 (49) No
8 3 27, 57, 60 52 (1) Yes Yes Yes 0 Yes
9 3 54, 59, 76 54 (2), 75 (1), 50 (1) Yes No Yes 0 No
10 2 55, 62 58 (2), 65 (6) Yes No Yes 1 (58) Yes
11 4 48, 53, 74, 85 85 (2), 48 (5), 50 (3), 51 (17),
53 (6)
Yes Yes Yes 2 (48, 51) Yes
MSI-V variable levels of MSI between lesions
a Families 2a and 2b are branches of the same family which were analysed separately due to independent segregation of affected status. Two
individuals with CRC were included as part of both families
Fig. 1 Family 1. Solid symbols, individuals with colorectal cancer.
Dotted symbols, individuals with large or atypical serrated polyps.
Individuals marked with two asterisks were genotyped for the
genome-wide linkage scan and for ﬁnemapping; those with a single
asterisk were typed for ﬁnemapping only. Affected individuals are
marked as such. A single individual in generation 2 with CRC was
also considered as affected. Numbers indicate age at ﬁrst onset of
cancer or polyps
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123interface version 5.05 [36]. Parametric linkage analysis
was performed under a dominant model with 60% pene-
trance, 10% phenocopy rate and disease allele frequency of
0.001. Affected-only parametric analysis was performed
using GeneHunter version 2.1, also under the easyLINK-
AGE interface, under a dominant model with 99% pene-
trance, 10% phenocopy rate and disease allele frequency of
0.001. For affected-only analysis, all individuals with
unknown or unaffected status were classed as unknown.
Marker map locations were based on the deCODE map
[37]; positions for markers not on the deCODE map were
interpolated from the nearest adjacent deCODE markers
using the NCBI Map Viewer Build 36.3 (http://www.
ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=
9606). Haplotypes were constructed by SimWalk and vis-
ualised using HaploPainter.
Sequencing of exons and exon–intron boundaries of
candidate genes was performed using BigDye Terminator
chemistry on an ABI 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA). Where possible,
variants were conﬁrmed by sequencing in both forward and
reverse directions.
Results
Genome-wide linkage screen
As there is currently little information on Jass syndrome in
the literature, the parameters used for linkage analysis were
estimated from the 11 families involved in the study. The
pattern of affected individuals was consistent with a
dominant mode of inheritance with 60% penetrance, and
four affected spouses out of 37 resulted in an estimated
phenocopy rate of 10%. Using these parameters, genome-
wide linkage analysis on Family 1 revealed regions of
interest at 2p25.2-p25.1 (logarithm of the odds (LOD) 1.36,
nonparametric linkage (NPL) score 4.50 (nominal
P = 0.004)), 2q24.3-q37.1 (LOD 1.38, NPL 4.62 (nominal
P = 0.003)), and 8p21.2-q12.1 (LOD 1.36, NPL 4.28
(nominal P = 0.007)) (Fig. 2), although none of these
attained genome-wide statistical signiﬁcance.
Finemapping
Finemapping using microsatellite markers spanning each
of the three regions of interest was carried out in Family 1
and a further 10 families (Supplementary Table 2). Family
2 showed independent segregation of affected status in two
branches, each of which met the criteria for inclusion, and
was therefore treated as two separate families for analysis,
2a and 2b. Five individuals overlapped between the two
branches and were therefore included in the analysis as part
of both Family 2a and Family 2b. In an effort to account for
some of the uncertainties inherent in a newly described
disease (such as penetrance, age at onset and the possibility
of a proportion of affected individuals being asymptom-
atic), three separate analyses were performed: parametric
analysis with full pedigrees, 10% phenocopy rate and 60%
penetrance; nonparametric analysis; and affected-only
Fig. 2 Genome-wide linkage screen on Family 1. a Parametric and b Nonparametric analysis
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123parametric analysis with 10% phenocopy rate and 99%
penetrance, in which unaffected individuals were retained
only if they were parents of affected individuals, or were
genotyped children of affected individuals for whom DNA
was unavailable; these individuals were assigned unknown
affected status.
LOD scores on chromosomes 2p and 8 were negative
throughout. Evidence for linkage to these regions was
limited, with no HLOD score greater than 0.6 and NPL
reaching signiﬁcance at the 5% level at a single location
only (marker D2S262 at 30 cM on chromosome 2p, NPL
1.36 (P = 0.044)) (Table 2).
Parametric analysis on full pedigrees at 2q revealed
LOD scores of 0.48 at 197 cM between markers D2S117
and D2S309, and 0.79 at 224 cM between markers
D2S163 and D2S401, with corresponding HLOD scores of
0.48 and 0.96, respectively (Table 2). Nonparametric
analysis revealed a single peak at 199 cM at D2S309 with
NPL 2.36 (P = 0.004), while the strongest evidence for
linkage in the affected-only analysis was at 193 cM
between markers D2S118 and D2S115, with LOD 1.12
and HLOD 2.09, with a secondary peak at 225 cM
between markers D2S163 and D2S133, with LOD 0.82
and HLOD 1.73 (Table 2; Fig. 3). Taking all three anal-
yses into account, the strongest evidence for linkage was
between markers D2S118 and D2S2309, with limited
evidence for linkage between markers D2S163 and
D2S133; these loci are deﬁned respectively as Region 1
and Region 2. Affected-only linkage analysis accounting
for heterogeneity gave estimates for the proportion of
linked families (a) as 0.54 for both Region 1 and Region 2
(Table 2). Results for individual families are summarised
in Supplementary Table 2.
Haplotype analysis at 2q and sequencing of candidate
genes
Eight families revealed a haplotype segregating with
affected status. Although there was no evidence of a
common haplotype shared between families, a consensus
region covering approximately 12 Mb, bordered at the
centromeric end by D2S117 and at the telomeric end by
D2S2358 and showing considerable overlap with Region 1,
segregated with affected status in 48/53 affected individ-
uals in seven families (Figs. 3, 4, Supplementary Table 2).
Of these, six families demonstrated variable MSI in cancers
and/or polyps (Table 1). In contrast, only one of the ﬁve
families not showing linkage to this region had variable
MSI. The consensus region contains 60 genes, from which
ﬁve (CFLAR, CASP10, CASP8, FZD7 and BMPR2) were
selected based on previous evidence in the literature for a
role in CRC or other cancers for sequencing of exons and
exon–intron boundaries. At least two affected members of
each family were screened, and where a variant showed
possible segregation with affected status the rest of the
family was also sequenced. Several variants were found,
including two CASP8 polymorphisms, namely a 6-nucle-
otide promoter insertion/deletion (rs3834129) and the
D302H SNP (rs1045485), with previously reported asso-
ciations with colorectal and other cancers [38–40]. Neither
these nor any other identiﬁed variants segregated with
affected status.
Exclusion of reported CRC susceptibility loci
The contribution of recently reported CRC susceptibility
loci on chromosomes 3, 7 and 9 to Jass syndrome was
Table 2 Finemapping results
Chr cM Parametric (full pedigrees) Nonparametric Affected only
LOD HLOD a NPL P LOD HLOD a
Regions identiﬁed from genome-wide screen on Family 1
2q (Region 1) 193–199 0.48 0.48 0.95 2.36 0.004 1.12 2.09 0.54
2q (Region 2) 224–231 0.79 0.96 0.60 1.75 0.018 0.82 1.73 0.54
2p 2–34 -1.06 0.04 0.15 1.36 0.04 -1.23 0.60 0.38
8 39–89 -1.56 0.00 0.00 0.86 0.14 -1.73 0.41 0.17
Chr cM Parametric (full pedigrees) Nonparametric Affected only
LOD HLOD NPL P LOD HLOD
Previously published CRC susceptibility loci
3 126–190 -1.22 0.18 0.57 0.27 -5.47 0.09
7 111–129 -2.76 0.00 0.83 0.15 -3.32 0.05
9 66–121 -1.86 0.00 0.37 0.42 -5.16 0.00
a proportion of linked families
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123tested using microsatellite markers selected to cover the
reported regions, and parametric, nonparametric and
affected-only analyses performed as above. No evidence
was found to support linkage (Table 2).
Discussion
Since the discoveries of the genes responsible for Familial
Adenomatous Polyposis, Lynch syndrome, and the ham-
artomatous polyposes, little progress has been made in the
identiﬁcation of genetic causes for the remaining unex-
plained majority of familial CRC. One of the reasons for
this lack of success is likely to be extensive genetic het-
erogeneity, which has proved to be a difﬁcult obstacle to
overcome for investigators undertaking linkage studies on
collections of CRC families. Other than exclusion of
known syndromes, approaches aimed at limiting the het-
erogeneity within a sample set have included enrichment
for families with young-onset cases [8, 41], exclusion of
multiple polyposis phenotypes [8], exclusion or inclusion
of adenomas and hyperplastic polyps [41, 42], and strati-
ﬁcation by occurrence of extracolonic cancers [41]. While
these approaches certainly limit phenotypic heterogeneity,
the extent to which they reduce genetic heterogeneity is
unknown.
The recent identiﬁcation of a familial predisposition to
colonic malignancies arising through the serrated pathway
[13, 14, 16, 43] has presented an opportunity to study a
subset of familial CRC in which genetic heterogeneity is
more limited. Serrated neoplasia families show distinct
features, such as variable levels of MSI and frequent
somatic BRAF mutation in tumours and a mixture of ser-
rated and adenomatous polyps, that allow them to be dis-
tinguished from the remainder of familial CRC. Such
features characterised families with evidence of linkage to
2q. Incomplete penetrance, small family size, under-
reporting due to a proportion of individuals being asymp-
tomatic, and practical difﬁculties in obtaining tumour and
polyp samples for all patients, however, mean that all
features will not be observed in all families. In an effort to
account for this, a set of criteria was developed for this
study that allowed for some ﬂexibility while still requiring
families to show a clustering of CRC and polyps in con-
junction with characteristics that deﬁne Jass syndrome. In
this attempt to include phenotypically homogeneous fam-
ilies, the possibility remains that a minority of these fam-
ilies may have a genetic predisposition different to that
Fig. 3 Finemapping at chromosome 2q in 11 Jass syndrome families.
Horizontal axis position along chromosome 2 in cM. a LOD score
from affected-only analysis; b HLOD from affected-only analysis
accounting for heterogeneity; c Nonparametric analysis. Shading
indicates location of haplotype sharing at Region 1
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123responsible for the majority of Jass syndrome. While this
leaves open the possibility of some families being incor-
rectly included, these are likely to be a minority.
A linkage strategy was selected that would maximise
the possibility of identifying linkage, while minimising the
effects of any heterogeneity that may remain within the
selected families. To this end, the family considered the
most likely to allow the identiﬁcation of a strong linkage
signal was subjected to a genome-wide linkage screen,
followed by ﬁnemapping of regions of interest in the
remaining 10 families. Loci at 2p25.2-p25.1, 2q24.3-q37.1
and 8p21.2-q12.1 were considered worthy of further
investigation, with 2q24.3-q37.1 showing the strongest
evidence of linkage. This region has also been identiﬁed in
three previous genome-wide linkage studies [4, 6, 12] and
one association study [40].
The consensus region at 2q32.2-q33.3 identiﬁed through
ﬁnemapping linkage and haplotype analyses contains ﬁve
genes that stand out as potential candidates and as a result
were prioritised for sequencing. CFLAR, CASP10 and
CASP8 are located in close proximity to each other at
2q33.1 and are all involved in the death receptor-induced
apoptotic pathway [44]. CASP8 somatic mutation has been
reported in CRC [45], and a CASP8 promoter polymor-
phism has been reported to be associated with
susceptibility to multiple cancers including CRC [40],
although the association has not been replicated in other
populations [46, 47]. CFLAR has attracted attention as a
therapeutic target as well as a potential oncogene due to its
role in the TRAIL pathway [48]. FZD7 is a member of the
Frizzled family which plays an important role in Wnt
signalling [49], central to the development and progression
of CRC [50], and has recently been shown to activate the
Wnt pathway in CRC cell lines [51]. BMPR2 inactivation
leads to epithelial cell proliferation and mixed polyp for-
mation in the mouse colon [52] and reduced protein
expression associated with somatic mutation is observed in
human CRC and cell lines [53]. Although sequencing of
these genes did not reveal any variants segregating with
disease, only coding regions and exon–intron boundaries
were sequenced, leaving noncoding regions, which may
harbour regulatory elements and potential splicing variants,
largely unexplored. With current re-sequencing technology
and exome capture, the investigation of the remaining
genes and regulatory regions becomes more feasible.
Several studies have reported evidence of linkage
among a proportion of non-syndromic CRC families, with
3q22, 7q31 and 9q22 prominent [4–6, 8–10, 12]. As well as
suggesting that they are unlikely to contribute to Jass
syndrome, the failure to ﬁnd evidence of linkage to these
Fig. 4 Haplotype analysis at
2q. Vertical lines show
chromosomal segments
segregating with affected status
within each family. Dark and
light shading show areas of
segregation at Region 1 and
Region 2 respectively
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123loci in the present study suggests that further character-
isation of the 3q22, 7q31 and 9q22 regions should aim to
exclude families demonstrating molecular and/or histo-
logical evidence of serrated neoplasia.
Approximately half of the families studied showed
evidence of linkage to 2q32.2-q33.3. The balance of the
families did not demonstrate linkage, suggesting that other
as yet unidentiﬁed loci may contribute to families with
serrated neoplasia. Continuing efforts to identify and
characterise serrated neoplasia families will serve the dual
purpose of allowing a greater understanding of the phe-
notypic presentation of the syndrome, and facilitating fur-
ther genetic studies which will allow conﬁrmation and
reﬁnement of the linked region, paving the way for more
comprehensive analysis of the locus, and potentially the
identiﬁcation of the underlying genetic defect.
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